Table 5.
Uni- and multivariate analyses of the PFS (12 months) of 42 GBM patients
| Variables | Univariate model | Multivariate model (P<0.001) | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Sex (male) | 1.235 | 0.510–2.992 | 0.640 | 1.613 | 0.652–3.993 | 0.301 |
| Age | 1.057 | 1.018–1.098 | 0.004 | 1.047 | 1.008–1.088 | 0.019 |
| ATF5 (low) | 0.285 | 0.113–0.719 | 0.008 | 0.366 | 0.141–0.953 | 0.039 |
| No TMZ treatment | 1.932 | 0.561–6.659 | 0.297 | |||
| No radiation therapy | 0.047* | 0–710.216* | 0.533 | |||
| ECOG | ||||||
| 4 | 1.000 | Reference | 0.122 | |||
| 3 | 3.737* | 0.294–47.585* | 0.310 | |||
| 2 | 0.569 | 0.050–6.467 | 0.649 | |||
| 1 | 0.652 | 0.138–3.088 | 0.590 | |||
| 0 | 0.282 | 0.058–1.378 | 0.118 | |||
| IDH wildtype | 0.447 | 0.100–2.004 | 0.293 | |||
| Ki67 staining (%) | 0.944 | 0.889–1.004 | 0.066 | |||
| Unmethylated MGMT promoter | 1.994 | 0.664–5.990 | 0.219 | |||
Notes: Uni- and multivariate analyses of the 12 months PFS was performed by applying the Cox proportional hazards model. Significant values are shown in bold.
*
HR calculation was affected by limited sample size.
Abbreviations: ECOG, Eastern Cooperative Oncology Group scale; GBM, glioblastoma; IDH, isocitrate dehydrogenase; MGMT, O-6-methylguanine-DNA methyltransferase; PFS, progression-free survival; TMZ, temozolomide.